Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol
|ClinicalTrials.gov Identifier: NCT00480883|
Recruitment Status : Completed
First Posted : May 31, 2007
Last Update Posted : June 2, 2010
Background: Cutaneous Leishmaniasis is a worldwide disease, endemic in over 88 countries, that has shown an increasing incidence over the last many decades. For the last 60 years antimony compounds are considered the treatment of choice. Though their use is expensive, cumbersome, has many adverse effects and not effective in all patients, the search for a better alternative is still going on. Low dose antimony compounds in combination with several agents have shown promise of reducing adverse effects of antimony compounds without compromising efficacy. Allopurinol is one such agent which though promising lacks randomized, controlled trials to prove efficacy. The main objective of this study is to evaluate low dose sodium stibogluconate in combination with allopurinol and to compare it with high dose sodium stibogluconate in terms of efficacy and adverse effects.
Methods and design: A multi-center randomized, controlled trial including 620 patients from endemic areas for Leishmaniasis in Pakistan will be undertaken to assess the research question. Parasitologically confirmed cutaneous leishmaniasis will be included in the study. After evaluating the inclusion/exclusion criteria patients will be randomized to receive either meglumine antimoniate (20 mg/kg/day/intramuscular, till clinical resolution or a maximum of 28 days) or combination of meglumine antimoniate (10 mg/kg/day intramuscular) and allopurinol (20 mg/kg/day/oral) till clinical resolution or a maximum of 28 days. During treatment patients will be admitted to hospital and monitored daily for the presence of adverse effects. Follow up period will last six months during which patients will visits the research centers for assessment of healing process at monthly intervals.
|Condition or disease||Intervention/treatment||Phase|
|Leishmaniasis, Cutaneous||Drug: meglumine antimoniate, allopurinol Drug: meglumine antimoniate||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||400 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate 20 Mg/Kg/Day Versus Meglumine Antimoniate 10 Mg/Kg/Day And Tablet Allopurinol 20 Mg/Kg/Day|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||June 2008|
|Actual Study Completion Date :||December 2008|
Active Comparator: 1
injection meglumine antimoniate 20 mg/kg/day/intramuscular for 21 days.
Drug: meglumine antimoniate
injectable 20 mg/kg/day/intramuscular for 21 days.
injection meglumine antimoniate 10 mg/kg/day/intramuscular plus tablet allopurinol 1200 mg/day/6hourly divided doses.
Drug: meglumine antimoniate, allopurinol
first drug in injectable, second is in tablet form.Drug: meglumine antimoniate, allopurinol
injectable meglumine antimoniate 10 mg/kg/day/intramuscular for 21 days plus tablet allopurinol 300mg/4times a day for 21 days.
- clinical healing of lesions. [ Time Frame: 3 months ]
- improvement of more than 50% in lesion size [ Time Frame: 3 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00480883
|Combined Military Hospital|
|Kharian Cantonment, Punjab, Pakistan, 74400|
|Principal Investigator:||AMER EJAZ, FCPS||Combined Military Hospital, Pakistan|